Washington is part of a coalition of states and territories asking a federal court to preliminarily approve a $400 million settlement with generic drugmakers Sandoz Inc. and Fougera Pharmaceuticals Inc. over allegations they conspired to raise prices and limit competition. The coalition filed its motion Oct. 1 in U.S. District Court for the District of Connecticut in Hartford. The proposed settlement would resolve claims of long-running antitrust violations; the allegations have not been established in court. Washington Attorney General Nick Brown said the alleged conduct harmed people who depend on prescription medicines. “Conspiring to charge Washington consumers more for the medicines they need is illegal and cruel,” Brown said in a statement. Consumers who purchased a generic prescription drug between May 2009 and December 2019 may qualify to submit a claim. Information is available at agg generic drugs dot com (www.AGGenericDrugs.com), by calling 1-866-290-0182 or emailing info@AGGenericDrugs.com. The coalition also says Washington and Idaho have secured restitution for businesses affected by the companies’ alleged practices; businesses can check eligibility at www.aggenericdrugs.com/English/CorporateEntities. The case is part of a broader series of multistate antitrust proceedings over generic drug prices that began in 2016, according to Brown. Court approval of the proposed settlement is still being sought.